Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (351-360 of 920) with videos related to

Pageof 92
Sort By:
World Journal of Urology|April 6, 2020
Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancerSami-Ramzi Leyh-Bannurah, Mykyta Kachanov, Pierre I Karakiewicz, et al.
Urology|October 30, 2009
A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinomaGiovanni Lughezzani, Claudio Jeldres, Hendrik Isbarn, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 27, 2013
Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohortFlorian Roghmann, Andreas Becker, Quoc-Dien Trinh, et al.
Urologic Oncology|October 24, 2020
Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomyLara Franziska Stolzenbach, Sophie Knipper, Philipp Mandel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 18, 2012
Marked heterogeneity of ERG expression in large primary prostate cancersSarah Minner, Michael Gärtner, Fabian Freudenthaler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
European Urology|August 15, 2006
Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Claudio Jeldres, et al.
European Urology Focus|June 11, 2019
Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trialPhilipp C Mandel, Hartwig Huland, Anne Tiebel, et al.
Pageof 92

Showing results (351-360 of 920) with videos related to

Sort By:
Pageof 92
World Journal of Urology|April 6, 2020
Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancerSami-Ramzi Leyh-Bannurah, Mykyta Kachanov, Pierre I Karakiewicz, et al.
Urology|October 30, 2009
A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinomaGiovanni Lughezzani, Claudio Jeldres, Hendrik Isbarn, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 27, 2013
Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohortFlorian Roghmann, Andreas Becker, Quoc-Dien Trinh, et al.
Urologic Oncology|October 24, 2020
Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomyLara Franziska Stolzenbach, Sophie Knipper, Philipp Mandel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 18, 2012
Marked heterogeneity of ERG expression in large primary prostate cancersSarah Minner, Michael Gärtner, Fabian Freudenthaler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2025
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapyMike Wenzel, Benedikt Hoeh, Carolin Siech, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
European Urology|August 15, 2006
Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Claudio Jeldres, et al.
European Urology Focus|June 11, 2019
Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trialPhilipp C Mandel, Hartwig Huland, Anne Tiebel, et al.
Pageof 92